Asset

Bupivacaine

Pacira BioSciences Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (18)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00745290phase3completed2008-08-012009-01-01Pacira Pharmaceuticals, IncA Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty
NCT00485693phase2completed2007-06-012009-08-01Pacira Pharmaceuticals, IncDose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty
NCT00485433phase2completed2007-06-012007-12-01Pacira Pharmaceuticals, IncDose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair
NCT00806806phase1completed2008-10-012009-02-01Pacira Pharmaceuticals, IncEvaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers
NCT03176459phase4completed2017-06-012018-11-20Pacira Pharmaceuticals, IncEvaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

FDA applications (1)

ApplicationTypeApplicant
NDA 022496NDAPACIRA PHARMACEUTICALS INC

Marketed products (2)

  • EXPAREL
  • EXPAREL